Oxford Biomedica PLC PDMR Dealing (2105C)

TIDMOXB

RNS Number : 2105C

Oxford Biomedica PLC

07 October 2022

PDMR Dealing

Oxford, UK - 7 October 2022 : Oxford Biomedica plc ("Oxford Biomedica" or the "Company") (LSE:OXB), a leading gene and cell therapy group, was informed that Matthew Treagus, Chief Information Officer, has purchased 1,390 ordinary shares of 50p each ("Ordinary Shares") in the Company on 7 October 2022 on the London Stock Exchange at a price of 355.6655p. Following this purchase Matthew Treagus holds 5,891 Ordinary Shares representing 0.00006% of the Company.

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.

 
 1.   Details of the Person Discharging Managerial Responsibility 
       ("PDMR") 
 a)   Name                            Matthew Treagus 
     ------------------------------  ----------------------------------- 
 2.   Reason for the notification 
     ------------------------------------------------------------------- 
 a)   Position/status                 Chief Information Officer 
     ------------------------------  ----------------------------------- 
 b)   Initial notification/           Initial Notification 
       amendment 
     ------------------------------  ----------------------------------- 
 3.   Details of the Issuer 
     ------------------------------------------------------------------- 
 a)   Name                            Oxford Biomedica plc 
     ------------------------------  ----------------------------------- 
 b)   LEI code                        213800S1GVQNXQ15K851 
     ------------------------------  ----------------------------------- 
 4.   Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of 
       transaction; (iii) each date; and (iv) each place where 
       transactions have been conducted 
     ------------------------------------------------------------------- 
 a)   Description of                  Ordinary Shares of 50 pence each 
       the financial 
       instrument 
                                       ISIN: GB00BDFBVT43 
       Identification 
       code 
     ------------------------------  ----------------------------------- 
 b)   Nature of the                   Purchase 
       transaction 
     ------------------------------  ----------------------------------- 
 c)   Price(s) and volumes(s)           Price(s)       Volume(s) 
                                         GBP3.556655    1,390 
                                                       ---------- 
     ------------------------------  ----------------------------------- 
 d)        Aggregated information 
             *    Aggregated volume     1,390 
 
                                        GBP4,943.75 
             *    Aggregated total 
     ------------------------------  ----------------------------------- 
 e)   Date of the transaction         07-10-2022 
     ------------------------------  ----------------------------------- 
 f)   Place of the transaction        London Stock Exchange, Main Market 
                                       (XLON) 
     ------------------------------  ----------------------------------- 
 

-Ends-

 
 For further information, please 
  contact: 
 
   Oxford Biomedica plc:                 Tel: [phone] 
   Natalie Walter, Company Secretary 
 

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector(R) platform, and is working on programmes from pre-clinical to commercial stage across a range of therapeutic areas with global partners.

Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In 2022, the Group established Oxford Biomedica Solutions, a US based subsidiary AAV manufacturing and innovation business, based near Boston, US.

Further information is available at www.oxb.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBKOBBDBDDAKK

(END) Dow Jones Newswires

October 07, 2022 07:28 ET (11:28 GMT)